Method for diagnosing and prognosing inflammatory bowel disease and crohn's disease

1. A method for distinguishing between complicated and non-complicated Crohn's disease in a subject, the method comprising,

providing a test sample from a subject diagnosed with Crohn's disease;

detecting a level of an anti-Glc(β1,3)Glc(β) antibody (ALCA) in said sample by binding of said ALCA in said sample to a carbohydrate reagent comprising an isolated Glc(β1,3)Glc(β) glycan;

detecting a level of an anti-GlcNAc(β1,4)GlcNAc(β) antibody (ACCA) in said sample by binding of said ACCA in said sample to a carbohydrate reagent comprising an isolated GlcNAc(β1,4)GIcNAc(β) glycan;

detecting a level of an anti-mannan antibody (ASCA) in said sample by binding of said ASCA in said sample to a carbohydrate reagent comprising an isolated mannan;

detecting a level of an anti-Man(α1,3)Man(α) antibody (AMCA) in said sample by binding of said AMCA in said sample to a carbohydrate reagent comprising an isolated Man(α1,3)Man(α); and

distinguishing a complicated disease course in said subject by detection of an elevated level of each of said ALCA, ACCA, ASCA, and AMCA in said test sample relative to a control reference sample from one or more individuals known to have non-complicated Crohn's disease.

2. The method of claim 1 , wherein said test sample is serum.

3. The method of claim 1 , wherein said antibodies are detected by an enzyme-linked immunosorbent assay (ELISA).

4. The method of claim 1 , wherein said isolated Glc(β1,3)Glc(β) glycan, said isolated GlcNAc(β1,4)GlcNAc(β) glycan, said isolated mannan, and said isolated Man(α1,3)Man(α) mannan are attached to a solid phase.

5. The method of claim 1 , wherein said complicated disease course comprises penetrating, fistulating, structuring, or fibrostenosing disease course.

6. The method of claim 1 , further comprising detecting a level of at least one additional antibody indicative of Crohn's Disease in said sample, wherein said additional antibody is selected from the group consisting of an anti-Man(α1,6)Man(α) antibody (AMBA), an anti-Man(α1,2)Man(α) antibody (AMNA), and an anti-α-Man antibody (AMA).

7. The method of claim 6 , wherein said method comprises detecting levels of two of said additional antibodies in said sample.

8. The method of claim 6 , wherein said method comprises detecting levels of each of said AMBA AMNA, and AMA in said sample.

9. The method of claim 6 , wherein said ASCA, said AMCA, said AMBA, said AMNA, and said AMA are IgG antibodies.

10. The method of 9 , wherein said anti-Glc(β1,3)Glc(β) antibody (ALCA) is an IgG antibody and said anti-GlcNAc(β1,4)GlcNAc(β) antibody (ACCA) is an IgA antibody.